Indium labeled IMP-205xm734
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colonic Neoplasms
Conditions
Colonic Neoplasms
Trial Timeline
Jul 1, 2005 → Dec 1, 2008
NCT ID
NCT00185081About Indium labeled IMP-205xm734
Indium labeled IMP-205xm734 is a phase 1 stage product being developed by Gilead Sciences for Colonic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00185081. Target conditions include Colonic Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00185081 | Phase 1 | Completed |
Competing Products
6 competing products in Colonic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzastaurin HCl | Eli Lilly | Phase 2 | 52 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo) | Pfizer | Pre-clinical | 22 |
| Methylnaltrexone Bromide (MNTX) + Placebo | Pfizer | Approved | 84 |
| oxaliplatin | Sanofi | Approved | 84 |
| Oxaliplatin (SR96669) | Sanofi | Phase 3 | 76 |